Novel selective β(1)-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease

β-Blockers reduce mortality and improve symptoms in people with heart disease; however, current clinically available β-blockers have poor selectivity for the cardiac β(1)-adrenoceptor (AR) over the lung β(2)-AR. Unwanted β(2)-blockade risks causing life-threatening bronchospasm and reduced efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Jillian G., Gardiner, Sheila M., Woolard, Jeanette, Fromont, Christophe, Jadhav, Gopal P., Mistry, Shailesh N., Thompson, Kevin S. J., Kellam, Barrie, Hill, Stephen J., Fischer, Peter M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Federation of American Societies for Experimental Biology 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471521/
https://www.ncbi.nlm.nih.gov/pubmed/28400472
http://dx.doi.org/10.1096/fj.201601305R

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471521/
https://www.ncbi.nlm.nih.gov/pubmed/28400472
http://dx.doi.org/10.1096/fj.201601305R

Ejemplares similares